We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 2,218

Patentability of parthenogenic stem cells - an update

  • Taylor Wessing
  • -
  • European Union, United Kingdom
  • -
  • September 29 2014

In June 2013, we reported that in International Stem Cell Corporation ("ISCC") v Comptroller General of Patents, another reference had been made to

Not all Bolar exemptions are the same - an update

  • Taylor Wessing
  • -
  • European Union, Germany, United Kingdom
  • -
  • September 26 2014

The 'regulatory review' defence, better known as the 'Bolar exemption' after a similar provision in US law, first came into force in October 2005

Recent decisions of the European Court of Justice of the European Union on SPCs: a few answers many questions

  • Grünecker
  • -
  • European Union
  • -
  • September 25 2014

Supplementary Protection Certificates (SPCs) were implemented in Europe in 1993 in order to compensate patentees in the pharmaceutical field for the

Patent transactions in the life sciences

  • Taylor Wessing
  • -
  • United Kingdom
  • -
  • September 24 2014

High research costs, complex regulatory requirements and dwindling opportunities for developing small-molecule targets: these are some of the factors

Isolated genetic material remains patentable in Australia

  • Henry Hughes
  • -
  • Australia
  • -
  • September 24 2014

The Full Federal Court of Australia has confirmed in a unanimous decision of 5 judges that isolated genetic material is patentable subject matter in

Novartis continues its successful injunction spree

  • Lakshmikumaran & Sridharan
  • -
  • India
  • -
  • September 24 2014

Novartis AG holds the patent for the drug containing the active pharmaceutical ingredients vildagliptin and vildagliptin in combination with

FDA goes purple on biologics and biosimilars: composes a variation on a theme of orange

  • Duane Morris LLP
  • -
  • USA
  • -
  • September 22 2014

Since the early 1980s, the pharmaceutical industry, as well as the pharmacy boards that control substitution at the state level, have relied on FDA's

Fair play?

  • Pillsbury Winthrop Shaw Pittman LLP
  • -
  • USA
  • -
  • September 20 2014

With blockbuster drugs reaching the end of their patent lives, many companies are looking for new ways to best secure their formulations and protect

Update on Australian Federal Court decision regarding patentability of isolated nucleic acid molecules

  • FB Rice
  • -
  • Australia
  • -
  • September 19 2014

On Tuesday 16th September, an application for special leave to appeal to the High Court was made on behalf of Yvonne D'Arcy, the appellant in the

Full Federal Court confirms isolated nucleic acids are patentable in Australia

  • Freehills Patent Attorneys
  • -
  • Australia
  • -
  • September 19 2014

The Full Federal Court has unanimously confirmed that isolated nucleic acids, either DNA or RNA, are patentable in Australia. The decision is in